Related Experiment Video
Updated: Jul 2, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Taxanes in the elderly: can we gain as much and be less toxic?
Laura Biganzoli1, Sara Licitra, Erica Moretti
1Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Piazza dell'Ospedale 2, 59100 Prato, Italy. lbiganzoli@usl4.toscana.it
Abstract:
Taxanes are very effective agents in several types of cancer. However, their activity is counterbalanced by side effects that could represent a limitation of their use in older cancer patients. This review aims at evaluating whether or not there are data supporting a tailored use of standard taxanes i.e. docetaxel and paclitaxel in elderly patients with the aim to increase their therapeutic index. In addition, recent data on the role of nanoparticle albumine-bound paclitaxel in breast cancer are discussed in this paper.
Related Concept Videos
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

